Eli Lilly & Co.
Revenue Breakdown
| Fiscal Year | Zyprexa | Cialis | Alimta | Humalog | Humulin | Gemzar | Evista | Forteo | Strattera | Symbyax | Erbitux | Byetta | Trad jenta | Effient | Jardiance | Trulicity | Taltz | Olumiant | Verzenio | Emgality | Tyvyt | Cyramza | Baqsimi | Retevmo | Bebtelovimab | Mounjaro | Jaypirca | Zepbound | Omvoh | Ebglyss | Kisunla | Animal Health | Collaboration and Other Revenue | Other Pharmaceutical Products |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2007 | $4.76B | $1.19B | $854.2M | $1.47B | $999.0M | $1.54B | $1.09B | $709.1M | $582.8M | $126.9M | $0 | $334.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5.08B |
| FY2008 | $4.70B | $1.44B | $1.15B | $1.73B | $1.06B | $1.72B | $1.08B | $778.6M | $579.4M | $103.5M | $0 | $420.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.05B | $0 | $4.55B |
| FY2009 | $4.92B | $1.56B | $1.71B | $1.96B | $1.00B | $1.36B | $1.01B | $843.0M | $598.0M | $84.1M | $0 | $390.8M | $0 | $36.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.21B | $0 | $5.15B |
| FY2010 | $5.03B | $1.70B | $2.21B | $2.05B | $1.09B | $1.15B | $1.03B | $816.7M | $609.4M | $0 | $0 | $0 | $0 | $114.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.39B | $0 | $5.89B |
| FY2011 | $4.62B | $1.88B | $2.46B | $2.38B | $1.26B | $498.4M | $1.07B | $949.7M | $619.6M | $0 | $0 | $0 | $114.7M | $302.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.68B | $0 | $6.48B |
| FY2012 | $1.70B | $1.93B | $2.59B | $2.40B | $1.32B | $361.3M | $1.01B | $1.15B | $620.0M | $0 | $0 | $0 | $248.8M | $452.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.04B | $0 | $4.78B |
| FY2013 | $1.17B | $2.16B | $2.70B | $2.61B | $1.41B | $283.7M | $1.05B | $1.24B | $708.2M | $0 | $0 | $0 | $480.9M | $508.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.15B | $0 | $6.64B |
| FY2014 | $1.04B | $2.29B | $1.80B | $2.79B | $1.40B | $0 | $419.6M | $1.32B | $731.4M | $0 | $0 | $0 | $622.3M | $522.6M | $47.4M | $19.0M | $0 | $0 | $0 | $0 | $0 | $28.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.35B | $0 | $4.24B |
| FY2015 | $1.04B | $2.31B | $2.47B | $2.84B | $1.31B | $0 | $0 | $1.35B | $784.0M | $0 | $683.3M | $0 | $429.6M | $518.5M | $85.6M | $248.3M | $0 | $0 | $0 | $0 | $0 | $384.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.18B | $0 | $2.32B |
| FY2016 | $816.3M | $2.47B | $2.16B | $2.84B | $1.28B | $0 | $0 | $1.50B | $752.4M | $0 | $687.2M | $0 | $457.6M | $509.3M | $285.9M | $925.7M | $113.1M | $0 | $0 | $0 | $0 | $614.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.16B | $0 | $2.62B |
| FY2017 | $549.4M | $2.32B | $2.06B | $2.84B | $1.34B | $0 | $0 | $1.75B | $617.7M | $0 | $653.2M | $0 | $480.0M | $528.2M | $447.5M | $2.03B | $559.2M | $0 | $9.3M | $0 | $0 | $758.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.09B | $0 | $2.44B |
| FY2018 | $485.4M | $2.16B | $2.12B | $3.00B | $1.34B | $0 | $0 | $1.58B | $623.1M | $0 | $637.3M | $0 | $529.6M | $470.1M | $658.3M | $3.20B | $937.5M | $13.6M | $129.4M | $162.5M | $0 | $821.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.20B |
| FY2019 | $343.3M | $890.6M | $1.69B | $2.82B | $1.29B | $0 | $0 | $1.41B | $698.8M | $0 | $0 | $0 | $503.7M | $0 | $944.8M | $4.13B | $1.37B | $42.4M | $580.4M | $162.5M | $0 | $925.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $248.5M | $4.48B |
| FY2020 | $0 | $622.1M | $1.25B | $2.63B | $1.23B | $0 | $0 | $1.05B | $816.0M | $0 | $0 | $0 | $478.2M | $0 | $1.24B | $5.05B | $1.79B | $88.4M | $912.7M | $383.9M | $0 | $883.3M | $0 | $0 | $810.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $309.8M | $5.13B |
| FY2021 | $0 | $810.0M | $1.23B | $2.45B | $1.22B | $0 | $0 | $802.2M | $790.0M | $0 | $0 | $0 | $0 | $0 | $1.49B | $6.47B | $2.21B | $111.4M | $1.35B | $550.8M | $0 | $1.03B | $0 | $0 | $2.24B | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $378.1M | $4.97B |
| FY2022 | $0 | $0 | $927.8M | $2.06B | $1.02B | $0 | $0 | $612.9M | $0 | $0 | $0 | $0 | $0 | $0 | $2.06B | $7.44B | $2.48B | $179.2M | $2.01B | $650.9M | $0 | $971.0M | $0 | $0 | $1.20B | $482.5M | $0 | $0 | $0 | $0 | $0 | $0 | $511.2M | $5.04B |
| FY2023 | $0 | $0 | $226.7M | $1.63B | $796.8M | $0 | $0 | $580.4M | $0 | $0 | $0 | $0 | $0 | $0 | $2.57B | $7.13B | $2.76B | $168.5M | $3.86B | $678.4M | $0 | $1.01B | $0 | $0 | $0 | $5.16B | $128.0M | $175.8M | $0 | $0 | $0 | $0 | $1.09B | $6.15B |
| FY2024 | $0 | $0 | $0 | $1.28B | $627.5M | $0 | $0 | $466.8M | $0 | $0 | $0 | $0 | $0 | $0 | $3.23B | $6.23B | $3.10B | $154.2M | $5.08B | $746.5M | $0 | $1.08B | $0 | $0 | $0 | $11.54B | $320.0M | $3.03B | $0 | $0 | $0 | $0 | $1.30B | $6.85B |
| FY2025 | $0 | $0 | $0 | $1.10B | $541.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.81B | $5.82B | $3.41B | $142.3M | $6.21B | $821.6M | $0 | $1.12B | $0 | $0 | $0 | $17.53B | $481.0M | $10.21B | $112.4M | $98.6M | $85.2M | $0 | $1.65B | $12.03B |